PTC will receive up to $25 million from Cystic Fibrosis Foundation Therapeutics in support of key Phase IIb clinical trials for PTC124 in cystic fibrosis (CF).
Stuart Peltz, president and CEO of PTC Therapeutics, said: “We look forward to initiating registration-directed studies of PTC124 for nonsense-mutation- mediated CF within the next few months.”